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Abstract: The global increase in cancer mortality and economic losses necessitates the cautious
quest for therapeutic agents with compensatory advantages over conventional therapies. Anticancer
peptides (ACPs) are a subset of host defense peptides, also known as antimicrobial peptides, which
have emerged as therapeutic and diagnostic candidates due to several compensatory advantages
over the non-specificity of the current treatment regimens. This review aimed to highlight the
ravaging incidence of cancer, the use of ACPs in cancer treatment with their mechanisms, ACP
discovery and delivery methods, and the limitations for their use. This would create awareness for
identifying more ACPs with better specificity, accuracy and sensitivity towards the disease. It would
also promote their efficacious utilization in biotechnology, medical sciences and molecular biology to
ease the severity of the disease and enable the patients living with these conditions to develop an
accommodating lifestyle.
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1. Introduction
Cancer is used synonymously to mean either malignant tumors or neoplasms and
refers to a group of diseases that affect any part of the human body [1]. According to the
World Health Organization (WHO), it is the leading cause of global mortality, accounting
for about 20 million deaths in 2020, in which the most common causes of death include
lung (1.80 million), colon and rectum (935,000), liver (830,000), stomach (769,000) and
breast (685,000) [2]. It occurs through the rapid formation of abnormal cells that develop
uncontrollably to invade the surrounding body parts and organs through the process of
metastasis, the primary cause of death from cancer [3]. Cancer affects all age groups, but the
incidence of cancer rises with age due to the build-up risk of specific cancers that increases
with age, coupled with the fact that the capacity for cellular amelioration mechanisms
becomes less effective with age [4].
The causes of cancer have been linked to a series of interactions between an indi-
vidual’s genetic factors and the three categories of external agents [5]. These external
agents include biological carcinogens through infections from some parasites, viruses and
bacteria [6]; physical carcinogens through the interaction with ultraviolet and ionizing
radiation [7]; and chemical carcinogens through exposure to asbestos, tobacco smoke, water
contaminants, such as arsenic, and food contaminants such as aflatoxins [8]. Approximately
thirteen percent of cancers diagnosed in 2018, for instance, were caused by carcinogenic
infections such as hepatitis B virus, hepatitis C virus, Epstein Barr virus, human papil-
lomavirus (HPV) and Helicobacter pylori [9]. Particularly, the risk of liver and cervical
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cancer increases with some HPV and Hepatitis B and C viruses, while the incidence of HIV
increases the risk of cervical cancer substantially [10].
Understanding the molecular mechanism of cancer formation from uncontrolled cell
division to tissue invasiveness can shed light on the mutations of genes and proteins
involved in cell cycle inactivation and suppression [11]. Epigenetic alterations have also
been reported in cancer, where some protein-coding genes were altered due to methylation
in colon cancer [12]. The epigenetic alterations implicated in DNA-repair genes that cause
reduced expression of DNA-repair proteins have been involved in cancer progression’s
genetic instability at the early stage [13]. Another cause of mutation in cancer is DNA-
mismatch repair or homologous recombinational repair (HRR) in defective cells 9899. DNA
repair inhibition has also been said to be involved in heavy metal-induced carcinogenicity.
At the same time, the regulatory activities of miRNAs can target and reduce the expression
of some protein-coding genes [14].
Appropriate and efficacious treatment is associated with early and correct cancer
diagnosis because every cancer treatment is related to a specific treatment regimen. The
current treatment regimens of cancer include immunotherapy, hormone therapy, stem cell
transplant, biomarker testing (the use of genes, proteins and other substances referred
to as tumor markers or biomarkers), radiotherapy, chemotherapy and surgery [15]. The
goal of these treatment procedures is primarily to either remove/kill cancer from the body
(primary treatment), to reduce the chance that cancer will recur by killing the remaining
cancer cells after primary treatment (adjuvant treatment) or to relieve the side effects of
treatment (palliative treatment). Despite these interventions, late side effects are associated
with these treatment regimens, which depend on the type of cancer being treated and where
in the body the cancer treatment is conducted [16]. Certain general side effects reported
include lymphedema, fertility issues, nerve problems, sexual health issues, urinary issues,
insomnia, anemia, loss of appetite, thrombocytopenia, constipation, delirium, diarrhea,
edema, fatigue and others. Researchers and the international community have called for a
more sensitive treatment regimen with little or no side effects to reduce cancer incidence
and its growing menace. The use of anticancer peptides (ACPs) would eliminate the
limitations of most cancer treatments, such as low solubility and restrictive and negative
side effects [17].
Host defense peptides (HDPs), also known as host-defense antimicrobial peptides
(AMPs), are key components of the innate immune system in all life forms, both vertebrates
and invertebrates. In fact, some invertebrates, such as insects and crustaceans, do not have
an adaptive immune system and use only the innate immune system for their protective
mechanism. HDPs have emerged as amphipathic and short cationic biomolecules of di-
verse sequences, synthesized from the cells and tissues of complex life forms [18]. HDPs
perform various functions, which include antimicrobial, anti-inflammatory, immunomodu-
latory, antioxidant, protease inhibitors, antiparasitic, and anticancer (the use of anticancer
peptides (ACPs)) functions [19]. Many HDPs have been identified, which differ in structure
and sequence and have been classified into α- helical peptides, β- sheets with disulfide
bridges, cyclic peptides, and peptides with extended flexible loop structures [20]. Several
HDP databases exist as a catalog for over 2600 naturally occurring anticancer peptides
(ACPs) [21]. However, synthetic ACPs for cancer treatment bring consistency and sta-
bility and allow for more consistent and accurate research results tailored to providing
the desired effect by binding to a specific receptor without interfering with other receptor
subtypes under proper usage conditions with fewer side effects and great benefits [22].
This review attempts to explore the biological importance of anticancer peptides (ACPs) in
the treatment of cancer through their mechanism of action and technologies used for their
identification and delivery, as well as their challenges.
2. Modes of Action of Host-Defense Peptides (HDPs)
HDPs have many modes of action, which seem to be conserved to some degree across
different cell types, which include bacteria and cancer cells [23]. Cationic HDPs can interact
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with the membrane of cancer cells as they predominantly contain negatively charged
molecules [24]. An example of such peptides is Leucine-leucine-37 (LL-37), which has
membranolytic activities (Table 1). Such cationic HDPs have an electrostatic interaction
with cancer cell membranes, which plays an important role in eliciting a cytotoxic effect on
the cancer cells [25,26]. Arias et al., 2020 [22] undertook a study to improve the anticancer
activity of synthetic HDPs. Arias et al., 2020 [22] could substitute an arginine for a lysine
amino acid, which resulted in an enhanced electrostatic interaction and selectivity for
Jurkat Leukemia cells compared to non-cancerous peripheral blood mononuclear cells.
It was observed that HDPs have the ability to interact with the cell membrane of cells,
such as bacteria, and neutralize the charge allowing the HDPs to further penetrate through
the membrane, thus increasing their cytotoxic effects [27]. It should be noted that cancer
cells have an abnormal cell membrane composition when compared to normal cells [28].
The fluidity of cell membranes may be determined by the cholesterol concentration and
distribution throughout the membrane. Cancer cells with lower cholesterol deposition will
have an increased sensitivity to certain HDPs [24,29]. A study by Frislev et al., 2017 [30]
observed the use of a liprotide HAMLET (human α-lactalbumin made lethal to tumor cells)
in order to kill cancer cells (Figure 1).
Figure 1. Adapted from Frisley et al., 2017 [30] which represents the liprotide complex, HAMLET, and the target organelles
in MCF7 (human breast adenocarcinoma cell line) cells. The HAMLET complex is comprised of α-lactalbumin and oleic acid.
The α-lactalbumin function in the complex is to retain the oleic acid (OA) in solution and transport the OA to vesicles of
MCF7 cells, increasing membrane fluidity (Frislev et al., 2017). Accessed at https://s100.copyright.com/CustomerAdmin/
PLF.jsp?ref=1054733c-0e16-42b8-9270-647b8f875da8 (accessed on 19 June 2021).
The study showed that the liprotides were able to increase the fluidity of the membrane.
The same study also observed that by knocking down Annexin A6, a protein that is
responsible for plasma membrane repair, they could enhance the liprotide’s killing effects.
A study by Mamusa et al., 2017 [31] observed that derivatives of the HAL-2 peptide were
able to directly damage yeast cell membranes resulting in increased death of the cells. The
same study also observed that, by replacing a methionine with a valine amino acid, the
therapeutic effect was decreased to all cells tested. These studies show that the composition
of the antimicrobial peptide is important and that making informed modifications may
result in enhanced therapeutic effects in different cell types such as bacterial or cancer cells.
Antimicrobial peptides have also been reported to interact with cell receptors in order
to either engage secondary effector proteins or initiate immunomodulatory processes such
as the inflammatory signaling pathways [32,33]. An example of such anticancer peptide
with immunomodulatory activities includes high mobility group box protein 1 (HMGB1)
(Table 1) [34]. It should be noted that the selective interaction of these HDPs is attributed
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to their physicochemical properties [32]. It has also been observed that identifying the
exact functions of HDPs is difficult as their expression levels may dictate the role they play
in processes such as inflammation (pro-inflammatory or anti-inflammatory) [32,35,36]. A
study by Li et al., 2019 [37] showed that the antimicrobial peptide LL-37 interacted with
the P2X7 receptor, which allowed for the internalization of the HDP into the cell. Once the
AMP LL-37 activated the P2X7 receptor, it induced pore formation in the membrane [38]. It
was observed that a scrambled form of LL-37 would not interact strongly with a neutral
membrane and cause the pore-forming phenomenon, showing how important the structure
of an antimicrobial peptide was to its ability to interact with receptors [37].
Research is ongoing to improve the therapeutic effects of ACPs while reducing their
toxicity [38]. In order to achieve the aforementioned goal, studies modifying natural
cationic ACPs have been performed. A study by Alexander et al., 2002 [39] performed a
study to observe the effects of AMPs to affect macromolecular synthesis. The study showed
that Pleurocidin derivatives at low levels were able to inhibit macromolecular synthesis
within cells while causing less damage to the cell membrane. This study shows that by
understanding the composition of AMPs and how they function, we may produce AMPs
that are active and effective at lower concentrations, which may reduce their toxicity.
Table 1. Mechanism of some HDPs used for the treatment of cancer forms.
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3. Novel Anticancer Peptides (ACPs) Used in Cancer Therapy
The negative charges exhibited more by cancer cells than by normal cells are con-
tributed by several factors: overexpression of heparan sulfate proteoglycans, the abundance
of zwitterionic phosphatidylethanolamine, PS overexpression, glycolipids glycosylation
deregulation, and membrane glycoproteins with O-glycosylation repeat [55]. The loss
of asymmetry of the phospholipid distribution within the extracellular and intracellular
plasma membrane layers in tumor cells exposes the tumor cells’ PS exterior [56]. Internaliz-
ing anticancer HDPs at the hydrophobic core also compromises the stiffness and fluidity of
the cancer cell membrane and promotes their lytic effects [51].
Several ACPs are available in the databases, such as antimicrobial database APD3
(https://wangapd3.com/database/antiC.php, accessed on 26 June 2021) for therapeutic
intervention against various cancer forms. Some of them include Magainin 2, which
creates pores during cell membrane damage to establish its anticancer activities against
human lung cancer cells, A59, and in Ehlrich’s murine ascites cells [47], Buforin IIb, which
disrupts the membrane using mitochondrial apoptosis to establish its anticancer activities
against leukemia, breast, prostate and colon cancer [57]. Brevenin-2R causes lysosomal
and autophagy-like cell death to T-cell leukemia Jurkat, B-cell lymphoma BJAB, colon
carcinoma HT29/219 and SW742, fibrosarcoma L929, breast adenocarcinoma MCF-7, and
lung carcinoma A549 cells [49]. Limnonectes fujianensis brevinvin penetrates the lipid
bilayer causing cell death to lung cancer H460, melanoma cell, glioblastoma U251MG, and
colon cancer HCT116 cell lines [49]. Phylloseptin-PHa penetrates the lipid bilayer causing
cell death to breast cancer cells MCF-7, breast epithelial cells MCF10A [50]. Ranatuerin-
2PLx establishes cell apoptosis using caspase-3 against prostate cancer cell PC-3 [51], and
Dermaseptins establishes pore formation of the prostate cancer cell PC-3 [52].
The novelty of the use of ACPs in the sensitive treatment of cancer has been well-
established, utilizing their structure and functional relationships. ACPs, such as LL-37—an
alpha-helical peptide that belongs to the cathelicidin family—are under clinical trials in a
phase I-II stage against melanoma using intratumor injection [40]. A nonamer peptide, LTX-
315—derived from structure–activity relationship studies of HDP bovine lactoferricin—has
also been tested as an efficacious drug either as a single or in combination with immune
checkpoint inhibitors (such as anti-CTLA4/anti-PD-1) for its effect of causing changes in a
tumor microenvironment such as an upsurge of T effector cells, necrosis of tumors and a
decrease in immunosuppressive cells in a human clinical trial (phase 1) [58]. The phase II
stage clinical trial of LTX-315 is ongoing to validate the intratumor administration for pa-
tients living with advanced metastatic sarcoma using tumor-infiltrating lymphocytes (TILs).
Dusquetide (SGX942), a novel innate defense regulator of both pathogen-associated molec-
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ular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by binding
p62, is being explored in phase III clinical trials against neck and head cancer [59]. D-K6L9,
in combination with IL-12, was found to reduce neovascularization in breast and prostate
cancer cell lines, while (KLAKLAK)2 uses apoptotic-induced-mitochondrial-membrane
damage to treat Hela cell lines [60,61]. Some novel ACPs are summarized in Table 1 against
different cancer forms as well as the mechanisms involved.
4. Mechanism of ACPs for Cancer Treatment
ACPs can exhibit anticancer activity through various mechanisms; mainly through
membrane disruption or pore formation. These membrane-active mechanisms are an
essential feature of ACPs, as the chance of resistance developing against this type of
treatment is low [60]. ACPs can also express anticancer activity through non-membranolytic
mechanisms by focusing on intracellular targets, mediating innate host immunity or
actively blocking pathways that lead to tumor formation.
The carpet model can describe one of the mechanisms of ACPs, which directly in-
volves cell membrane disruption. This carpet model starts with HDP, which is positively
charged and interacts with a negatively charged phospholipid located on the outer layer
of the cell membrane. This interaction causes the peptides to align parallel to the cell
membrane without protruding into the phospholipid bilayer and, in turn, covering the cell,
thus it is termed ‘carpet.’ Once enough peptides protect the cell membrane, a threshold
concentration will be reached. Then, the peptides start to rotate on themselves and insert
into the membrane, causing permeabilization of the cell membrane. The continuation of
this process will ultimately lead to the formation of micelles (Figure 2) [60]. A study by
Arias et al. [22] demonstrated the membrane disruption mechanism of ACP Tritrp-Arg by
incorporating fluorescent dye propidium iodide (PI) into the treatment of Jurkat cells. This
study showed an increase in PI fluorescent intensity, indicating that the cell membrane
was permeated, and the fluorescent dye could bind to the DNA within the cell. Specific
examples of these ACPs are indicated in Table 1.
Figure 2. Carpet model. In this model, HDP can disrupt the membrane by orienting parallel to the
surface of the lipid bilayer and forming a carpet like layer, in which membrane permeation will occur.
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In the barrel and stave model (Figure 3), transmembrane channels are formed from
the collection of monomer peptides on the cell membrane; the monomer peptides undergo
a structural change and aggregate together to form the ‘stave’ within the membrane bilayer.
The insertion process is the result of the aggregation, which forces the peptides into the
lipid core region; the insertion of the peptide creates a hydrophilic channel that blocks off
the hydrophobic part of the bilayer. Once the channel has formed, more monomers will be
accumulated to further increase the channel’s size. In addition, the cell membrane is also
weakened due to the hydrophobic forces exerted by the peptide. At the moment, the only
known ACP that employs this mechanism is alamethicin [43].
Figure 3. Barrel and stave model. In this model, HDP attaches to the cellular membrane and
aggregates. HDP is then inserted into the membrane bilayer so that the hydrophobic peptide regions
align with the lipid core region, and the hydrophilic peptide regions form the interior region of
the pore.
The toroidal pore (Figure 4) can be described as temporary holes within the cell
membrane created by host defense peptides that are long enough to span across the bilayer
before the disintegration of the membrane. The host defense peptides will align parallel to
the cell membrane. Once the peptides reach a certain concentration, the peptides will start
to insert into the membrane causing the lipid layer to bend inwards, resulting in a toroidal-
like pore structure, which is lined by the polar head of the lipid layer and the inserted
peptide [60,62]. The toroidal pore allows for host defense peptides to gain access to the
intracellular space of the cell, where peptides can disrupt pathways that are responsible for
DNA replication, protein synthesis, or permeating the mitochondrial membrane. Examples
of host defense peptides that use this mechanism include cecropin A, protegrin-1 and
magainin-2 [62].
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Figure 4. Toroidal pore model. Prior to membrane permeation, HDP, which is aggregated on the
membrane surface, will cause the single layer lipid to bend inwards so that the pore is lined by both
inserted HDP and the lipid head of the membrane.
Host defense peptides capable of translocation across cellular membranes can trigger
apoptosis via disruption of the mitochondria. The host defense peptides, which can enter
the intracellular space of the cell through the pores, will permeate the membrane of the
mitochondria, which will result in the expulsion of protein cytochrome c. The release
of cytochrome c will cause a cascade of effects whereby Apaf-1 oligomerization will be
activated followed by the activation of caspase 9, which will lead to the conversion of
pro-caspase 3 to caspase 3. The caspase 3, in turn, will induce apoptosis [63]. Host defense
peptides, such as LL-37 and CATH-2, which has previously been shown to be able to cross
the cell membrane and induce apoptosis [64].
Anticancer inhibition can also occur without directly acting on the cancerous cell
membrane. Certain host defense peptides can actively compete for binding sites, blocking
pathways that lead to cancer formation (Figure 5). We can see this demonstrated using
synthetic peptide BLBD, which can bind to β-catenin and LEF-1 sites, which results in
the decreased formation of breast cancer cells [65]. In addition, certain pathways require
protein to undergo conformational changes, such as dimerization or isomerization, before
binding to active sites; host defense peptides can be used to bind and merge with these
proteins, ultimately disabling them [66,67].
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Figure 5. Image showing that the host defense peptide can act on tumors/cancer through various
mechanisms. (a) Competitively bind to the sites of precursor proteins and thus preventing down-
stream interaction; (b) Simulate the conformation regulation domain of the target protein to inhibit
its conformation dependent activation; (c) Target cancer cells to improve efficacy of chemotherapy
drugs; (d) Cancerous cell membrane disruption; (e) Mediate immunity.
Peptides can also be used to target tumor cells to make for more efficient drug delivery
and to enhance the effects of chemotherapy drugs. This peptide has already been used in
Phase I/II clinical trials for advanced solid tumors. For example, the peptide BT1718 will
target overexpressed MMP14 sites found in tumor growth and improve drug delivery and
efficiency [68]. Another way that the host defense peptides can be used for the treatment
of cancer is by mediating the body’s own immune system. Peptides such as alloferon-1
and alloferon-2 found in insect venom can induce natural killer cells in mammals. Cancer
treatment with only alloferon-1 has shown cancer suppression activity close to the results
from a low dose of chemotherapy [67].
In cancer treatment, peptides can be used in a variety of ways. This includes the use of
peptides as medications (for example, as angiogenesis inhibitors), tumor-targeting agents
that transport cytotoxic pharmaceuticals and radionuclides (targeted chemotherapy and
radiation therapy), hormones and vaccinations [69]. Proapoptotic peptides, for instance
DP1, could be used to treat a variety of solid human tumors such as head and neck cancers,
melanomas, and papillomas. This primary application of ACPs could be an adjuvant to
pre-existing treatment methods such as chemotherapy or radiotherapy [70].
Transient pore formation is another mechanism used by HDPs to establish their effects.
Melittin, for instance, can bind on the vesicle translocated and redistributed on both sides
of the membrane to induce stable and transient membrane permeabilization above a critical
peptide-to-lipid ratio at the nanomolar range that allows for the transmembrane conduction
of atomic ions without glucose or larger molecule leakage [71]. HDPs also use electropo-
ration to establish functional domains of intracellular peptides or to gain insight into the
peptide inhibition of signal transduction in adherent cells, such as chondrocytes, through
transiently forming pores [43]. The use of membrane depolarization is another mechanism
utilized by the HDPs to establish their therapeutic effects through the release of cellular
contents, leading to death [72]. For instance, abeta-induced membrane depolarization
in PC12 cells has been seen to be sensitive to metabotropic glutamate receptor mGluR(1)
antagonists and to pertussis and cholera toxins with the involvement of G-protein.
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5. Discovery Techniques for the Identification of Sensitive HDPs
Several technologies have been explored to identify HDPs of novel importance. Bakare
et al., 2020 [20] used the HMMER (a name given by the software developers Sean Eddy
and Travis Wheeler) and other in silico technologies to develop putative ACPs that could
target the ligand-binding sites of cadherin-1 to monitor the peptides’ prognostic efficacy in
patients living with cancer. HMMER is used to identify homologous protein or nucleotide
sequences and sequence alignment to discover more sensitive peptides [73]. Grafskaia
et al., 2018 [74] used transcriptomic technologies in combination with in silico analysis
to discover ten novel synthetic antimicrobial peptides from the sea anemone Cnipodus
japonicas, three of which were verified to be potent against bacterial strains. Transcriptomic
technologies are used to study the sum of an organism’s RNA transcripts, giving rise to the
genome’s ability to synthesize biomolecules within the cells and control its gene expression
regulation [75].
More potent, cost-effective, broad-spectrum HDPs have been developed by Liu et al.,
2020 [76] using advanced computer-assisted design strategies to address challenging prob-
lems of translating a primary sequence to peptide structures to solve myriad multi-drug
resistance problems. Fields et al., 2020 [77] used a machine learning approach and a simple
biophysical trait to develop 20-amino acid bacteriocin peptides that can traverse the mem-
brane of pathogens causing cytotoxic, antimicrobial and hemolytic activities. Antimicrobial
peptides with potent and broad-spectrum activities have also been recently designed using
molecular engineering technologies to elucidate the peptide motifs and translation oppor-
tunities to explore rational design for industrial collaboration [78]. Molecular engineering
technologies are being explored in this regard to design and test molecular properties,
behavior and interactions in order to assemble better peptides, systems and processes for
specified functions [79].
Apart from this, Aruleba et al., 2018 [80] studied the ligand-binding sites and molecu-
lar docking interaction of Slc2a4 as a target for the treatment of cancer with putative HDPs
using HMMER for the discovery of the peptides. Wang, 2017 [81] described the discovery,
design and treatment strategies of HDPs using the conserved genes from the genomic and
proteomic approaches outside the HDP genes with experimental validation, which guaran-
tee a complete mapping utilizing the procedures of sequence shuffling, library screening,
hybridization and de novo design. Tucker et al., 2018 [82] used bacterial self-screening
of surface-displayed peptide libraries to discover diverse physicochemical parameters of
next-generation antimicrobials to unravel the current limitations of peptide applications.
Molecular dynamic (MD) approaches have been adopted to study the relationship between
the biological function and mechanism of HDPs to optimize these antibiotic candidates.
In silico technologies, such as HMMER, with molecular validation techniques have also
been used to explore the use of novel HDPs as diagnostic candidates against three bacterial
pneumonias and HIV with great promise for industrial collaborations in a lateral flow
device [83,84].
6. Molecular Validation Techniques Used for HDPs
Several anticancer peptides (ACPs) have been discovered to manage cancer and other
diseases, which are being subjected to molecular validation to ascertain their activities and
application in terms of sensitivity and specificity. Tincho et al., 2016 [85] used molecular
methods, such as cell viability, cytotoxicity and other anti-HIV assays, to show the anti-HIV
activities of HDPs against HIV gp120 and NL4-3 receptors. The use of cell viability for
peptides’ molecular validation has limitations because cell viability is very diverse due
to the redox potential of the cell population, cell membrane integrity, or the activity of
cellular enzymes that form a snapshot of cytotoxicity or drug efficacy [86]. Even specially
designed cell viability indicators, such as fluorescence microscopes, microplate readers or
flow cytometers, have positive and negative attributes with their sensitivity, reliability and
compatibility being determined by relevant cell lines [87].
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Williams et al., 2017 [84] employed site-directed mutagenesis to generate variant
HDPs from previously identified ones and used molecular validation techniques, such as a
lateral flow device (LFD) binding assay and nanotechnologies recombinant technologies,
to explore their activities against HIV p24. The advantages of the use of LFD include
easy pick-up from testing sites and pharmacies, with the fast generation of results within
30 min, thus making it popular [88]. However, researchers compared 5869 people with
both an LFD and a PCR test in mass testing in Liverpool. Seventy of these people were
positive from the PCR tests and, of these 70, only 28 were positive on LFD tests, showing a
sensitivity of about 40% [89]. Cardoso et al., 2021 [78] enumerated the molecular targets
and mechanisms involved in several HDPs’ activities and pharmacokinetics. An example
of a molecular target that binds one or more signaling peptides or signaling proteins is
tropomyosin-receptor kinase B (TrkB), which is bound and activated by the neurotrophic
protein brain-derived neurotrophic factor (BDNF) [90]. Prada-Prada et al., 2020 [91] used
circular dichroism, cytotoxicity, minimum inhibitory concentration (MIC), growth and time-
kill kinetics to explore Ib-M’s mechanisms and structural activities of peptides against E
coli. Scanning electron microscopy (SEM), transmission electron microscopy [73], NaCl per-
meability, agarose diffusion, and inhibitory concentration assays were utilized to evaluate
the hemolytic activities, toxicity, stability and mechanism of action of chicken hemoglobin
HDPs [92]. These technologies, as listed, are necessary to assess and ensure the specific
activities of the optimized peptides for clinical trials with negligible toxicity. Regmi et al.,
2017 [93] highlighted the combinatorial drug therapy of HDP from Bacillus amyloliquefa-
ciens with beta-lactams evaluating its stability, MIC, susceptibility testing, synergy testing
and antibiofilm property against pathogens. This combined application of two or more
HDPs or the use of antibiotics with HDPs is very promising to prevent the development of
antimicrobial resistance and provide the susceptible host with an optimized therapy [94].
7. Challenges for the Use of Anticancer Peptides (ACPs) in Cancer Treatment
Many advancements were made in cancer therapy because of the complications
experienced with cancerous cells’ resistance to cancer treatments and the low specificity of
the currently employed drugs in chemotherapy [95]. The anti-neoplastic drugs, presently
used in cancer treatments, consist of various damaging side effects, mainly because they
target rapidly dividing cells rather than only cancerous cells [96]. Thus, anticancer peptides
(ACPs) provide an alternative anticancer drug [95]. ACPs are beneficial because they
differentiate between neoplastic and non-neoplastic cells, which interact specifically with
the negatively charged membrane components (these differ between cancer and non-cancer
cells [95]. ACPs have a similar ability, in which these peptides have specificity towards
malignant cells [96]. Despite the several effective in vivo studies published on ACPs, none
of these approaches have made it onto the market [95]. The challenges for using ACPs in
cancer treatments are the poor bioavailability of peptides, the toxicity of peptides, immune
response to treatments, and the cost-inefficiency of these approaches.
In the cancer treatment serum, proteolytic degradation is a major threat to the po-
tency of the antitumor peptides [96,97], as this promotes unspecific binding to the serum
components, reducing the half-life of these molecules in the serum, leading to proteolytic
degradation, thus decreasing the bioavailability and affecting the stability of the serum.
To overcome these challenges, research needs to be conducted to improve the pharma-
codynamic properties of the serum. Baker et al., 1993 [97] successfully exhibited this
phenomenon of bioavailability of the peptides by introducing D-amino acids or substitut-
ing naturally occurring L-amino acids by diastereomers, such that the peptides’ cytotoxicity
was decreased against normal, non-cancerous cells and that these diastereomers peptides
maintained their anticancer activities. Ultimately, these researchers recorded a reduction in
serum inactivation and enzymatic degradation in in vivo studies [98]. Other approaches
were also taken by introducing vector-mediated delivery of the genes that encode the active
anticancer peptides [80], using various delivery systems (liposomes, polymer nanoparticles
or quantum dots [96]. Some of the naturally occurring ACPs and some synthetic ACPs
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are more stable in the serum, especially synthetic ACPs containing D-amino acids, which
confer stability against proteolytic degradation [96].
All anticancer peptides (ACPs) represent a degree of anticancer activity. However, not
all these peptides are suitably selective against cancer cells [96]. In cancer treatments, the
hydrophobicity of the peptides is essential for membrane penetration, and a fundamental
advocate of the membrane interactions of peptides is amphiphilicity. ACPs promote tumor
tissue penetration and therefore kill target cells rapidly by perturbing the integrity of the
plasma membrane. The problem arises when peptides showing cancer cell specificity only
fall within a narrow range of 0.53–0.78 and have non-tilted helical peptide structures, when
these specific peptides, with further analysis, indicate toxic effects to both cancerous and
non-cancerous cells and when tilted helical peptides represent a nonspecific means of cell
membrane lysis. Therefore, research needs to be conducted that focuses on the structure of
peptides, and the activity relationship needs to be further understood to design promising
novel antitumor agents [95].
The introduction of foreign ACPs into a host can elicit treatment neutralizing antibod-
ies and/or cause potentially harmful allergic responses in cancer patients [96]. Thus, a few
approaches have been considered to overcome this problem. To avoid causing deleterious
anti-ACP immune responses, the introduction of host-defense peptides (HDPs) could be a
possible alleviation strategy, or the co-administration of foreign ACPs with immunosup-
pressive drugs. Alternatively, the encapsulation of ACPs in liposomes that are engineered
to deliver their cargo straight to the tumor sites could be promising, as this minimizes the
opportunity for the host to acquire anti-ACP immunity [96].
In most new treatment approaches, the cost efficiency of the process is always a
major setback. In the case of ACPs and AMPs, the cost of isolating naturally occurring
ACPs and even the production of synthetic ACPs tends to exceed the costs of the normal
production of conventional chemotherapeutic agents that are currently employed in cancer
treatments [95,98]. This is not a problem with lipopeptides and other small peptides since
chemoenzymatic methods and solution synthesis are employed to generate them; however,
when it comes to large peptides, the production costs increase [99].
8. Conclusions
The challenges of cancer treatment procedures and associated side effects have ne-
cessitated the quest for new therapeutic interventions to combat its menace. ACPs have
demonstrated potential therapeutic efficacy against different forms of cancer because of
their specificity and the inability of tumors to develop resistance towards them. To this
end, this review provides a comprehensive account of novel anticancer ACPs ranging
from modes of action, relevant ACPs used in cancer treatment, mechanisms of action,
molecular validation, technologies employed in their discovery, and limitations for their
use as anticancer agents. It is essential to state that the different structures in terms of
amino acid composition and residues gave rise to variation in the mechanisms of action
of various ACPs and their targets for cancer therapy. Utilizing the strategies from this
review would enhance the development of more sensitive and specific HDPs to solve
cancer incidence completely.
Author Contributions: A.G., O.O.B., L.-A.N., R.W., A.K. and M.K. wrote the manuscript. O.O.B., A.G.
and M.K. edited and checked the manuscript. All authors contributed to the article and approved the
submitted version. All authors have read and agreed to the published version of the manuscript.
Funding: Financial support received by O.O.B., a recipient of an NRF Post-Doctoral Fellowship
(Grant number: 120712). L.N. was funded by the National Research Foundation of South Africa
(NRF), R.W. was financially supported by the University of the Western Cape. This research was also
financially supported by the NRF to M.K. (Grant numbers: 116346 and 109083), A.K. (Grant numbers:
107023 and 115280), and A.G. (Grant number: 129493). Part of the research was funded by a DST-NRF
Centre of Excellence in Food Security award (Project ID: 170202) and GrainSA (GB0200066).
Institutional Review Board Statement: Not applicable.
Biomolecules 2021, 11, 1120 14 of 17
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: The authors would like to thank the various institutions, namely, the University
of the Western Cape and the University of Free State, for infrastructure and administrative support.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the
design of the review, in the collection and interpretation of literature, in the writing of the manuscript,
or in the decision to publish the review.
References
1. Saxena, M.; van der Burg, S.H.; Melief, C.J.; Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 2021, 21, 360–378.
[CrossRef]
2. Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory:
Cancer Today; International Agency for Research on Cancer: Lyon, France, 2018. Available online: https://gco.iarc.fr/today
(accessed on 5 June 2021).
3. Black, J.R.; McGranahan, N. Genetic and non-genetic clonal diversity in cancer evolution. Nat. Rev. Cancer 2021, 21, 379–392.
[CrossRef] [PubMed]
4. Marunaka, Y. Roles of interstitial fluid pH and weak organic acids in development and amelioration of insulin resistance. Biochem.
Soc. Trans. 2021, 49, 715–726. [CrossRef]
5. Link, A.; Bornschein, J.; Thon, C. Helicobacter pylori induced gastric carcinogenesis-the best molecular model we have? Best
Pract. Res. Clin. Gastroenterol. 2021, 50–51, 101743. [CrossRef]
6. Calabrese, E.J.; Priest, N.D.; Kozumbo, W.J. Thresholds for carcinogens. Chem. Biol. Interact. 2021, 341, 109464. [CrossRef]
7. Si, H.; Yang, Q.; Hu, H.; Ding, C.; Wang, H.; Lin, X. Colorectal cancer occurrence and treatment based on changes in intestinal
flora. Semin. Cancer Biol. 2021, 70, 3–10. [CrossRef] [PubMed]
8. Miranda-Galvis, M.; Loveless, R.; Kowalski, L.P.; Teng, Y. Impacts of environmental factors on head and neck cancer pathogenesis
and progression. Cells 2021, 10, 389. [CrossRef] [PubMed]
9. de Martel, C.; Georges, D.; Bray, F.; Ferlay, J.; Clifford, G.M. Global burden of cancer attributable to infections in 2018: A
worldwide incidence analysis. Lancet Glob. Health 2020, 8, e180–e190. [CrossRef]
10. Stelzle, D.; Tanaka, L.F.; Lee, K.K.; Khalil, A.I.; Baussano, I.; Shah, A.S.; McAllister, D.A.; Gottlieb, S.L.; Klug, S.J.; Winkler, A.S.
Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob. Health 2021, 9, e161–e169. [CrossRef]
11. Chen, H.; Wang, J.P.; Liu, H.; Li, H.; Lin, Y.-C.J.; Shi, R.; Yang, C.; Gao, J.; Zhou, C.; Li, Q. Hierarchical transcription factor and
chromatin binding network for wood formation in Populus trichocarpa. Plant Cell 2019, 31, 602–626. [CrossRef]
12. Rosselló-Tortella, M.; Llinàs-Arias, P.; Sakaguchi, Y.; Miyauchi, K.; Davalos, V.; Setien, F.; Calleja-Cervantes, M.E.; Piñeyro, D.;
Martínez-Gómez, J.; Guil, S. Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon
cancer. Proc. Natl. Acad. Sci. USA 2020, 117, 20785–20793. [CrossRef] [PubMed]
13. Riaz, N.; Blecua, P.; Lim, R.S.; Shen, R.; Higginson, D.S.; Weinhold, N.; Norton, L.; Weigelt, B.; Powell, S.N.; Reis-Filho, J.S.
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat. Commun. 2017, 8, 857.
[CrossRef]
14. Li, H.-J.; Wu, N.-L.; Pu, C.-M.; Hsiao, C.-Y.; Chang, D.-C.; Hung, C.-F. Chrysin alleviates imiquimod-induced psoriasis-like skin
inflammation and reduces the release of CCL20 and antimicrobial peptides. Sci. Rep. 2020, 10, 2932. [CrossRef]
15. Key, N.S.; Khorana, A.A.; Kuderer, N.M.; Bohlke, K.; Lee, A.Y.; Arcelus, J.I.; Wong, S.L.; Balaban, E.P.; Flowers, C.R.; Francis, C.W.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J. Clin.
Oncol. 2020, 38, 496–520. [CrossRef]
16. Anwanwan, D.; Singh, S.K.; Singh, S.; Saikam, V.; Singh, R. Challenges in liver cancer and possible treatment approaches. Biochim.
Biophys. Acta BBA Rev. Cancer 2020, 1873, 188314. [CrossRef]
17. Ng, C.X.; Lee, S.H. The Potential Use of Anticancer Peptides (ACPs) in the Treatment of Hepatocellular Carcinoma. Curr. Cancer
Drug Targets 2020, 20, 187–196. [CrossRef]
18. Mookherjee, N.; Anderson, M.A.; Haagsman, H.P.; Davidson, D.J. Antimicrobial host defence peptides: Functions and clinical
potential. Nat. Rev. Drug Discov. 2020, 19, 311–332. [CrossRef]
19. Bosso, A.; Di Maro, A.; Cafaro, V.; Di Donato, A.; Notomista, E.; Pizzo, E. Enzymes as a Reservoir of Host Defence Peptides. Curr.
Top. Med. Chem. 2020, 20, 1310–1323. [CrossRef]
20. Bakare, O.O.; Fadaka, A.O.; Keyster, M.; Pretorius, A. Structural and molecular docking analytical studies of the predicted ligand
binding sites of cadherin-1 in cancer prognostics. Adv. Appl. Bioinform. Chem. AABC 2020, 13, 1–9. [CrossRef]
21. Bakare, O.O.; Fadaka, A.O.; Klein, A.; Pretorius, A. Dietary effects of antimicrobial peptides in therapeutics. All Life 2020, 13,
78–91. [CrossRef]
22. Arias, M.; Haney, E.F.; Hilchie, A.L.; Corcoran, J.A.; Hyndman, M.E.; Hancock, R.E.; Vogel, H.J. Selective anticancer activity of
synthetic peptides derived from the host defence peptide tritrpticin. Biochim. Biophys. Acta BBA Biomembr. 2020, 1862, 183228.
[CrossRef] [PubMed]
Biomolecules 2021, 11, 1120 15 of 17
23. Németh, T.; Sperandio, M.; Mócsai, A. Neutrophils as emerging therapeutic targets. Nat. Rev. Drug Discov. 2020, 19, 253–275.
[CrossRef] [PubMed]
24. Kunda, N.K. Antimicrobial peptides as novel therapeutics for non-small cell lung cancer. Drug Discov. Today 2020, 25, 238–247.
[CrossRef]
25. Kardani, K.; Bolhassani, A. Antimicrobial/anticancer peptides: Bioactive molecules and therapeutic agents. Immunotherapy 2021,
13, 669–684. [CrossRef]
26. Al-Smadi, M.; Al-Momani, F. Synthesis, characterization and antimicrobial activity of new 1, 2, 3-selenadiazoles. Molecules 2008,
13, 2740–2749. [CrossRef]
27. Marqus, S.; Pirogova, E.; Piva, T.J. Evaluation of the use of therapeutic peptides for cancer treatment. J. Biomed. Sci. 2017, 24, 21.
[CrossRef]
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